Once-monthly growth hormone set for progress as Versartis raises new funds
This article was originally published in Scrip
Executive Summary
Versartis completed a $25 million Series C venture funding round to support development of VRS-317, a once-monthly form of recombinant human growth hormone (rhGH) for the treatment of growth hormone deficiency (GHD) in pediatric patients.